Etanercept Biosimilar SDZ ETN Demonstrates Efficacy, Safety in Rheumatic Disease
Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.
Docus Herbert Kellner Herbert Kellner Department Of Rheumatology Neuwittelsbach Hospital Disease Activity Score Erythrocyte Sedimentation Rate
Source: hcplive.com